表觀遺傳修飾在干擾素治療乙型肝炎病毒感染中的作用

StephenW

表觀遺傳修飾在干擾素治療乙型肝炎病毒感染中的作用
楊志靜 1 2 , 孫寶珍 3 , 景城向 1 2 , 韓武 1 2 , 邵寧 1 2 , 明昊 1 2 , 陸昌 1 2 , 劉慧敏 1 2 , 王東旭 4 , 劉偉偉 1 2
隸屬關係
隸屬關係

    1
    【作者單位】： 吉林大學口腔醫院口腔頜面外科;
    2
    【作者單位】： 吉林大學口腔醫院吉林省牙齒發育與骨改建重點實驗室;
    3
    【作者單位】： 吉林大學中日聯合醫院肝膽胰外科;
    4
    吉林大學動物科學學院實驗動物中心，長春

    PMID：36325353 PMCID：PMC9618964 DOI：10.3389/fimmu.2022.1018053

免費 PMC 文章
抽象的

人類乙型肝炎病毒 (HBV) 是一種小型的、有包膜的 DNA 病毒，可引起急性和慢性肝炎。慢性乙型肝炎（CHB）與肝細胞癌發病機制有關。干擾素 (IFN) 長期以來一直用於治療慢性乙型肝炎，其優點包括治療持續時間短和病毒學反應持續。目前，各種證據表明，病毒共價閉合環狀 DNA (cccDNA) 和宿主基因組的表觀遺傳修飾對於病毒活性的調節至關重要。這種修飾包括組蛋白乙酰化、DNA 甲基化、N6-甲基腺苷和非編碼 RNA 修飾。 CHB 的 IFN 治療可以刺激多個 IFN 刺激的基因以抑制病毒複製。干擾素還可以通過表觀遺傳調節影響 HBV 生命週期。在這篇綜述中，我們總結了 IFN-α 抑制 HBV 複製的不同機制，包括表觀遺傳調控。此外，還討論了 IFN 活性的潛在機制，這表明它具有作為 CHB 新療法的潛力。有人提出，組蛋白乙酰化、DNA甲基化、m6A甲基化等表觀遺傳變化可能是IFN的靶點，這可能為HBV治療提供一種新方法。

關鍵詞：CcccDNA；乙肝病毒；干擾素治療； ISG；表觀遺傳調控。

版權所有 © 2022 楊、孫、向、吳、闞、郝、常、劉、王、劉。
利益衝突聲明

作者聲明，該研究是在沒有任何可能被解釋為潛在利益衝突的商業或財務關係的情況下進行的。處理編輯在審閱時聲明與作者有共同的父母關係。

StephenW

Role of epigenetic modification in interferon treatment of hepatitis B virus infection
Zhijing Yang  1   2 , Baozhen Sun  3 , Jingcheng Xiang  1   2 , Han Wu  1   2 , Shaoning Kan  1   2 , Ming Hao  1   2 , Lu Chang  1   2 , Huimin Liu  1   2 , Dongxu Wang  4 , Weiwei Liu  1   2
Affiliations
Affiliations

    1
    Department of Oral and Maxillofacial Surgery, Hospital of Stomatology, Jilin University, Changchun, China.
    2
    Jilin Provincial Key Laboratory of Tooth Development and Bone Remodeling, Hospital of Stomatology, Jilin University, Changchun, China.
    3
    Department of Hepatobiliary and Pancreas Surgery, China-Japan Union Hospital of Jilin University, Changchun, China.
    4
    Laboratory Animal Center, College of Animal Science, Jilin University, Changchun, China.

    PMID: 36325353 PMCID: PMC9618964 DOI: 10.3389/fimmu.2022.1018053

Free PMC article
Abstract

Human hepatitis B virus (HBV) is a small, enveloped DNA virus that causes acute and chronic hepatitis. Chronic hepatitis B (CHB) is associated with hepatocellular carcinoma pathogenesis. Interferons (IFNs) have been used for the treatment of CHB for a long time, with advantages including less treatment duration and sustained virological response. Presently, various evidence suggests that epigenetic modification of the viral covalently closed circular DNA (cccDNA) and the host genome is crucial for the regulation of viral activity. This modification includes histone acetylation, DNA methylation, N6-methyladenosine, and non-coding RNA modification. IFN treatment for CHB can stimulate multiple IFN-stimulated genes for inhibiting virus replication. IFNs can also affect the HBV life cycle through epigenetic modulation. In this review, we summarized the different mechanisms through which IFN-α inhibits HBV replication, including epigenetic regulation. Moreover, the mechanisms underlying IFN activity are discussed, which indicated its potential as a novel treatment for CHB. It is proposed that epigenetic changes such as histone acetylation, DNA methylation, m6A methylation could be the targets of IFN, which may offer a novel approach to HBV treatment.

Keywords: CccDNA; HBV; IFN therapy; ISGs; epigenetic regulation.

Copyright © 2022 Yang, Sun, Xiang, Wu, Kan, Hao, Chang, Liu, Wang and Liu.
Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor declared a shared parent affiliation with the authors at the time of review.

StephenW

https://www.frontiersin.org/arti ... mu.2022.1018053/pdf